Engineered antibodies

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 129-134

  Hudson, Peter J ^a   Souriau, Christelle ^a  

^a CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; BASILIXIMAB; CROFAB; DACLIZUMAB; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; EDRECOLOMAB; EFALIZUMAB; ENZYME; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; INFLAMMATORY ANTIBODY; INFLIXIMAB; LIPOSOME; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RADIOISOTOPE; REAGENT; RECOMBINANT ANTIBODY; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOXIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING AFFINITY; BIOSENSOR; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG BINDING; DRUG DESIGN; DRUG INTOXICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; ISOTOPE LABELING; LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN RNA BINDING; PSORIASIS; RADIOIMMUNOTHERAPY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SNAKEBITE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

RESPIRATORY SYNCYTIAL VIRUS;

EID: 0037235949     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0103-129     Document Type: Review

References (82)

1. Milstein, C. With the benifit of hindsight. Immunol. today 21, 359-364 (2000).
2. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001).
3. Hudson, P.J. & Souriau, C. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 1, 845-855 (2001).
4. Wiseman, G.A. et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94, 1349-1357 (2002).
5. Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
6. Ober, R.J., Radu, C.G., Ghetie, V. & Ward, E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559 (2001).
7. He, Y. et al. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169, 595-605 (2002).
8. 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl. Med. 42, 1519-1527 (2001).
9. Adams, G.P. et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61, 4750-4755 (2001).
10. Tomlinson, I. & Holliger, P. Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol. 326, 461-479 (2000).
11. Todorovska, A. et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248, 47-66 (2001).
12. Nielsen, U.B., Adams, G.P., Weiner, L.M. & Marks, J.D. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60, 6434-6440 (2000).
13. 2 constructs in a breast carcinoma xenograft model. Clin. Cancer Res. 7, 1061-1072 (2001).
14. Yazaki, P.J. et al. Tumor targeting of radiometal-labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem. 12, 220-228 (2001).
15. Gura, T. Therapeutic antibodies: magic bullets hit the target. Nature 417, 584-586 (2002).
16. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280 (2002).
17. 2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51, 15-24 (2002).
18. Goldenberg, D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713 (2002).
19. Casey, J.L. et al. Tumour targeting of humanised cross-linked divalent-Fab′ antibody fragments: a clinical phase I/II study. Br. J. Cancer 86, 1401-1410 (2002).
20. Leong, S.R. at. al. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 16, 106-119 (2001).
21. Fujioka, Y. et al. Renal metabolism of 3′-iodohippuryl Nε-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjug. Chem. 12, 178-185 (2001).
22. 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. Nucl. Med. Biol. 29, 139-146 (2002).
23. Segal, D.M., Weiner, G.J. & Weiner, L.M. Introduction: bispecific antibodies. J. Immunol. Methods 248, 1-6 (2001).
24. Carter, P. Bispecific human IgG by design. J. Immunol. Methods 248, 7-15 (2001).
25. Kipriyanov, S.M. et al. Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol. 169, 137-144 (2002).
26. Chester, K.A. et al. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis. Markers 16, 53-62 (2000).
27. Rippmann, J.F., Pfizenmaier, K., Mattes, R., Rettig, W.J. & Moosmayer, D. Fusion of the tissue factor extracellular domain to a tumor stroma-specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. Biochem. J. 349 (Pt. 3), 805-812 (2000).
28. Kreitman, R.J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2, 313-325 (2001).
29. Rybak, S.M. & Newton, D.L. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin. Biol. Ther. 1, 995-1003 (2001).
30. van Beusechem, V.W. et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. 76, 2753-2762 (2002).
31. Park, J.W. et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181 (2002).
32. Shi, N., Boado, R.J. & Pardridge, W.M. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18, 1091-1095 (2001).
33. Kousparou, C.A., Epenetos, A.A. & Deonarain, M.P. Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. Int. J. Cancer 99, 138-148 (2002).
34. O'Connell, D., Becerril, B., Roy-Burman, A., Daws, M. & Marks, J.D. Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol. 321, 49-56(2002).
35. Hoogenboom, H.R. & Chames, P. Natural and designer binding sites made by phage display technology. Immunol. Today 21, 371-378 (2000).
36. Krebs, B. et al High-throughput generation and engineering of recombinant human antibodies. J. Immunol. Methods 254, 67-84 (2001).
37. Nagy, Z.A. et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 8, 801-807 (2002).
38. Poul, M.A., Becerril, B., Nielsen, U.B., Morisson, P. & Marks, J.D. Selection of tumor-specific internalizing human antibodies from phage libraries. J. Mol. Biol. 301, 1149-1161 (2000).
39. Hanes, J., Schaffitzel, C., Knappik, A. & Pluckthun, A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18, 1287-1292 (2000).
40. Huie, M.A. et al. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc. Natl. Acad. Sci. USA 98, 2682-2687 (2001).
41. Liu, B., Huang, L., Sihlbom, C., Burlingame, A. & Marks, J.D. Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol. 315, 1063-1073 (2002).
42. Willemsen, R.A. et al. A phage display-selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 8, 1601-1608 (2001).
43. de Wildt, R.M., Tomlinson, I.M., Ong, J.L. & Holliger, P. Isolation of receptor-ligand pairs by capture of long-lived multivalent interaction complexes. Proc. Natl. Acad. Sci. USA 99, 8530-8535 (2002).
44. Wilson, D.S., Keefe, A.D. & Szostak, J.W. The use of mRNA display to select high-affinity protein-binding peptides. Proc. Natl. Acad. Sci. USA 98, 3750-3755 (2001).
45. Irving, R.A., Coia, G., Roberts, A., Nuttall, S.D. & Hudson, P.J. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. J. Immunol. Methods 248, 31-45 (2001).
46. Weng, S. et al. Generating addressable protein microarrays with PROfusion covalent mRNA-protein fusion technology. Proteomics 2, 48-57 (2002).
47. Xu, L. et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem. Biol. 9, 933 (2002).
48. Boder, E.T., Midelfort, K.S. & Wittrup, K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. USA 97, 10701-10705 (2000).
49. Daugherty, P.S., Iverson, B.L. & Georgiou, G. Flow cytometric screening of cell-based libraries. J. Immunol. Methods 243, 211-227 (2000).
50. de Graaf, M., van der Meulen-Muileman, I.H., Pinedo, H.M. & Haisma, H.J. Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol. Biol. 178, 379-387 (2002).
51. Powers, D.B. et al. Expression of single-chain Fv-Fc fusions in Pichia postoris. J. Immunol. Methods 251, 123-135 (2001).
52. Neuberger, M.S. et al. Diversification and selection mechanisms for the production of protein repertoires: lessons from the immune system. Appl. Biochem. Biotechnol. 83, 53-60 (2000).
53. Wu, H. et al. Stepwise in vitro affinity maturation of Vitaxin, an αvβ33-specific humanized mAb. Proc. Natl. Acad. Sci. USA 95, 6037-6042 (1998).
54. Kurtzman, A.L. et al. Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr. Opin. Biotechnol. 12, 361-370 (2001).
55. van der Linden, R.H., de Geus, B., Frenken, G.J., Peters, H. & Verrips, C.T. Improved production and function of Ilama heavy chain antibody fragments by molecular evolution. J. Biotechnol. 80, 261-270 (2000).
56. Poltoratsky, V. et al. Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation. Proc. Natl. Acad. Sci. USA 98, 7976-7981 (2001).
57. Saphire, E.O. et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
58. Desmyter, A., Decanniere, K., Muyldermans, S. & Wyns, L. Antigen specificity and high-affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 276, 26285-26290 (2001).
59. (H)3 domains. Biochemistry 41, 3628-3636 (2002).
60. Nuttall, S.D. et al. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 38, 313-326 (2001).
61. van den Beucken, T. et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310, 591-601 (2001).
62. Muyldermans, S. Single-domain camel antibodies: current status. J. Biotechnol 74, 277-302 (2001).
63. Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).
64. Meanwell, N.A. & Krystal, M. Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discov. Today 5, 241-252 (2000).
65. Parren, P.W. & Burton, D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77, 195-262 (2001).
66. Maynard, J.A. et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20, 597-601 (2002).
67. Nowakowski, A. et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99, 11346-11350 (2002).
68. Lecerf, J.M. et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98, 4764-4769 (2001).
69. Mhashilkar, A.M. et al. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 9, 307-319 (2002).
70. Arafat, W. et al. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Ther. 7, 1250-1256 (2000).
71. Cochet, O. et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58, 1170-1176 (1998).
72. Goncalves, J. et al. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 30, 32036-32045 (2002).
73. Worn, A. et al. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. 275, 2795-2803 (2000).
74. Tse, E. et al. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317, 85-94 (2002).
75. Visintin, M. et al. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317, 73-83 (2002).
76. Sanz, L. et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 9, 1049-1053 (2002).
77. Marty, C. et al. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer 87, 106-112 (2002).
78. Eshhar, Z., Waks, T., Bendavid, A. & Schindler, D.G. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248, 67-76 (2001).
79. thor Straten, P. et al. In situ cytokine therapy: redistribution of clonally expanded T cells. Eur. J. Immunol. 31, 250-258 (2001).
80. Lunde, E., Western, K.H., Rasmussen, I.B., Sandlie, I. & Bogen, B. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J. Immunol. 168, 2154-2162 (2002).
81. Robinson, W.H. et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 8, 295-301 (2002).
82. The Journal of the American Medical Association. Bioterrorism articles. http://pubs.amaassn.org/bioterr.html.